256 related articles for article (PubMed ID: 25071012)
1. Hypoxia suppresses cylindromatosis (CYLD) expression to promote inflammation in glioblastoma: possible link to acquired resistance to anti-VEGF therapy.
Guo J; Shinriki S; Su Y; Nakamura T; Hayashi M; Tsuda Y; Murakami Y; Tasaki M; Hide T; Takezaki T; Kuratsu J; Yamashita S; Ueda M; Li JD; Ando Y; Jono H
Oncotarget; 2014 Aug; 5(15):6353-64. PubMed ID: 25071012
[TBL] [Abstract][Full Text] [Related]
2. Isolinderalactone suppresses human glioblastoma growth and angiogenic activity in 3D microfluidic chip and in vivo mouse models.
Park JH; Kim MJ; Kim WJ; Kwon KD; Ha KT; Choi BT; Lee SY; Shin HK
Cancer Lett; 2020 May; 478():71-81. PubMed ID: 32173479
[TBL] [Abstract][Full Text] [Related]
3. Hypoxia upregulates HIG2 expression and contributes to bevacizumab resistance in glioblastoma.
Mao XG; Wang C; Liu DY; Zhang X; Wang L; Yan M; Zhang W; Zhu J; Li ZC; Mi C; Tian JY; Hou GD; Miao SY; Song ZX; Li JC; Xue XY
Oncotarget; 2016 Jul; 7(30):47808-47820. PubMed ID: 27329597
[TBL] [Abstract][Full Text] [Related]
4. Neuropilin-1 modulates TGFβ signaling to drive glioblastoma growth and recurrence after anti-angiogenic therapy.
Kwiatkowski SC; Guerrero PA; Hirota S; Chen Z; Morales JE; Aghi M; McCarty JH
PLoS One; 2017; 12(9):e0185065. PubMed ID: 28938007
[TBL] [Abstract][Full Text] [Related]
5. Aspirin Affects Tumor Angiogenesis and Sensitizes Human Glioblastoma Endothelial Cells to Temozolomide, Bevacizumab, and Sunitinib, Impairing Vascular Endothelial Growth Factor-Related Signaling.
Navone SE; Guarnaccia L; Cordiglieri C; Crisà FM; Caroli M; Locatelli M; Schisano L; Rampini P; Miozzo M; La Verde N; Riboni L; Campanella R; Marfia G
World Neurosurg; 2018 Dec; 120():e380-e391. PubMed ID: 30144594
[TBL] [Abstract][Full Text] [Related]
6. Increased Antiangiogenic Effect by Blocking CCL2-dependent Macrophages in a Rodent Glioblastoma Model: Correlation Study with Dynamic Susceptibility Contrast Perfusion MRI.
Cho HR; Kumari N; Thi Vu H; Kim H; Park CK; Choi SH
Sci Rep; 2019 Jul; 9(1):11085. PubMed ID: 31366997
[TBL] [Abstract][Full Text] [Related]
7. Macrophage migration inhibitory factor downregulation: a novel mechanism of resistance to anti-angiogenic therapy.
Castro BA; Flanigan P; Jahangiri A; Hoffman D; Chen W; Kuang R; De Lay M; Yagnik G; Wagner JR; Mascharak S; Sidorov M; Shrivastav S; Kohanbash G; Okada H; Aghi MK
Oncogene; 2017 Jun; 36(26):3749-3759. PubMed ID: 28218903
[TBL] [Abstract][Full Text] [Related]
8. CD44 expression in the tumor periphery predicts the responsiveness to bevacizumab in the treatment of recurrent glioblastoma.
Nishikawa M; Inoue A; Ohnishi T; Yano H; Kanemura Y; Kohno S; Ohue S; Ozaki S; Matsumoto S; Suehiro S; Nakamura Y; Shigekawa S; Watanabe H; Kitazawa R; Tanaka J; Kunieda T
Cancer Med; 2021 Mar; 10(6):2013-2025. PubMed ID: 33543833
[TBL] [Abstract][Full Text] [Related]
9. Acquired resistance to anti-VEGF therapy in glioblastoma is associated with a mesenchymal transition.
Piao Y; Liang J; Holmes L; Henry V; Sulman E; de Groot JF
Clin Cancer Res; 2013 Aug; 19(16):4392-403. PubMed ID: 23804423
[TBL] [Abstract][Full Text] [Related]
10. SDF-1 Blockade Enhances Anti-VEGF Therapy of Glioblastoma and Can Be Monitored by MRI.
Deng L; Stafford JH; Liu SC; Chernikova SB; Merchant M; Recht L; Martin Brown J
Neoplasia; 2017 Jan; 19(1):1-7. PubMed ID: 27940247
[TBL] [Abstract][Full Text] [Related]
11. Clonal ZEB1-Driven Mesenchymal Transition Promotes Targetable Oncologic Antiangiogenic Therapy Resistance.
Chandra A; Jahangiri A; Chen W; Nguyen AT; Yagnik G; Pereira MP; Jain S; Garcia JH; Shah SS; Wadhwa H; Joshi RS; Weiss J; Wolf KJ; Lin JG; Müller S; Rick JW; Diaz AA; Gilbert LA; Kumar S; Aghi MK
Cancer Res; 2020 Apr; 80(7):1498-1511. PubMed ID: 32041837
[TBL] [Abstract][Full Text] [Related]
12. Regulation of hypoxia-induced autophagy in glioblastoma involves ATG9A.
Abdul Rahim SA; Dirkse A; Oudin A; Schuster A; Bohler J; Barthelemy V; Muller A; Vallar L; Janji B; Golebiewska A; Niclou SP
Br J Cancer; 2017 Sep; 117(6):813-825. PubMed ID: 28797031
[TBL] [Abstract][Full Text] [Related]
13. Perspective: targeting VEGF-A and YKL-40 in glioblastoma - matter matters.
Holst CB; Pedersen H; Obara EAA; Vitting-Seerup K; Jensen KE; Skjøth-Rasmussen J; Lund EL; Poulsen HS; Johansen JS; Hamerlik P
Cell Cycle; 2021 Apr; 20(7):702-715. PubMed ID: 33779510
[TBL] [Abstract][Full Text] [Related]
14. Endothelial cell-derived angiopoietin-2 is a therapeutic target in treatment-naive and bevacizumab-resistant glioblastoma.
Scholz A; Harter PN; Cremer S; Yalcin BH; Gurnik S; Yamaji M; Di Tacchio M; Sommer K; Baumgarten P; Bähr O; Steinbach JP; Trojan J; Glas M; Herrlinger U; Krex D; Meinhardt M; Weyerbrock A; Timmer M; Goldbrunner R; Deckert M; Braun C; Schittenhelm J; Frueh JT; Ullrich E; Mittelbronn M; Plate KH; Reiss Y
EMBO Mol Med; 2016 Jan; 8(1):39-57. PubMed ID: 26666269
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of Combination Therapy with MET and VEGF Inhibitors for MET-overexpressing Glioblastoma.
Okuda T; Tasaki T; Nakata S; Yamashita K; Yoshioka H; Izumoto S; Kato A; Fujita M
Anticancer Res; 2017 Jul; 37(7):3871-3876. PubMed ID: 28668888
[TBL] [Abstract][Full Text] [Related]
16. Anti-VEGF antibody therapy induces tumor hypoxia and stanniocalcin 2 expression and potentiates growth of human colon cancer xenografts.
Miyazaki S; Kikuchi H; Iino I; Uehara T; Setoguchi T; Fujita T; Hiramatsu Y; Ohta M; Kamiya K; Kitagawa K; Kitagawa M; Baba S; Konno H
Int J Cancer; 2014 Jul; 135(2):295-307. PubMed ID: 24375080
[TBL] [Abstract][Full Text] [Related]
17. Dual inhibition of PFKFB3 and VEGF normalizes tumor vasculature, reduces lactate production, and improves chemotherapy in glioblastoma: insights from protein expression profiling and MRI.
Zhang J; Xue W; Xu K; Yi L; Guo Y; Xie T; Tong H; Zhou B; Wang S; Li Q; Liu H; Chen X; Fang J; Zhang W
Theranostics; 2020; 10(16):7245-7259. PubMed ID: 32641990
[No Abstract] [Full Text] [Related]
18. VEGF-C sustains VEGFR2 activation under bevacizumab therapy and promotes glioblastoma maintenance.
Michaelsen SR; Staberg M; Pedersen H; Jensen KE; Majewski W; Broholm H; Nedergaard MK; Meulengracht C; Urup T; Villingshøj M; Lukacova S; Skjøth-Rasmussen J; Brennum J; Kjær A; Lassen U; Stockhausen MT; Poulsen HS; Hamerlik P
Neuro Oncol; 2018 Oct; 20(11):1462-1474. PubMed ID: 29939339
[TBL] [Abstract][Full Text] [Related]
19. Interferon-regulatory factor-1 (IRF1) regulates bevacizumab induced autophagy.
Liang J; Piao Y; Henry V; Tiao N; de Groot JF
Oncotarget; 2015 Oct; 6(31):31479-92. PubMed ID: 26362401
[TBL] [Abstract][Full Text] [Related]
20. Anti-VEGF therapies for malignant glioma: treatment effects and escape mechanisms.
Miletic H; Niclou SP; Johansson M; Bjerkvig R
Expert Opin Ther Targets; 2009 Apr; 13(4):455-68. PubMed ID: 19335067
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
